IDH1 and central nervous system cancer: Triptolide, a potent Nrf2 inhibitor, has been shown to effectively suppress patient-derived IDH1-mutated glioma cells and exhibited selective cytotoxicity to preclinical glioma xenograft with IDH1 mutations [81].